Log In
Print this Print this

BMS-986202 (formerly AM152)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionOral lysophosphatidic acid receptor 1 (LPAR1; (EDG2) antagonist
Molecular Target Lysophosphatidic acid receptor 1 (LPAR1) (EDG2) (LPA1)
Mechanism of ActionLysophosphatidic acid receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF); Treat lung fibrosis of scleroderma and idiopathic pulmonary fibrosis (IPF); Treat pulmonary fibrosis
Regulatory Designation U.S. - Orphan Drug (Treat idiopathic pulmonary fibrosis (IPF))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today